GID BIO, Inc.

What GID BIO, Inc. does

GID BIO, Inc. is a privately held, pre-commercial medical device company developing an investigational autologous cellular therapy for knee osteoarthritis. The company's lead product, SVF Cell Injection Therapy, is built around its proprietary SVF-2 closed-loop tissue-processing platform, which harvests a small lipoaspirate from the patient, enzymatically dissociates and concentrates stromal vascular fraction cells inside a single sterile disposable canister, confirms a guaranteed therapeutic dose of over 25 million cells at the point of care, and delivers the preparation into the intra-articular joint under imaging guidance. The entire procedure is designed to be completed in approximately three hours in an outpatient setting without a separate laboratory or overnight stay, and the company is pursuing FDA Premarket Approval based on a completed Phase 3 clinical trial that reported 73% pain reduction and 115% function improvement at one year versus sham control with zero serious adverse device effects.

The company is headquartered in Louisville, Colorado, and operates with a small team (1-10 employees) under the legal entity GID BIO, Inc. (doing business as The GID Group, Inc.), incorporated in Arizona. Its target customer base is enterprise orthopedic practices and outpatient surgery centers that treat knee osteoarthritis patients who have exhausted standard conservative options but wish to avoid or delay total knee replacement; the company plans to launch through a selective physician partner program supported by clinical specialists for first cases.

GID BIO has no product revenue today and anticipates monetizing via a one-time per-procedure commercial model on FDA approval, supported by contemplated CMS reimbursement. The company has disclosed approximately $7.58 million across four funding rounds between 2010 and 2020, including grants from the Richard King Mellon Foundation. Its leadership combines medical device operational experience (Zimmer Biomet, St. Jude Medical, WebMD, KPMG) with public-company governance pedigree on the board (formerly of Yahoo!, Delta Airlines, Morgan Stanley, Wyvern Capital).

Name

GID BIO, Inc.

Legal name

GID BIO, Inc.

Website

https://gidbio.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

GID BIO, Inc. is a pre-commercial medical device company developing SVF Cell Injection Therapy, an investigational autologous point-of-care cellular treatment for knee osteoarthritis built on its proprietary SVF-2 closed-loop tissue-processing platform, targeting outpatient surgery centers pending FDA PMA.

Ownership category

akta.pro rank

Product category

Orthopedic Cellular Therapy / Regenerative Medicine

NAICS

Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Hip & Knee Reconstruction (Arthroplasty) (HLAKALAH)

Keywords

• Autologous cell therapy
• Point-of-care cellular therapy
• Stromal vascular fraction processing
• Orthopedic regenerative medicine
• Knee osteoarthritis treatment

Headquarters

HQ city

Louisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. SVF Cell Injection Therapy (Future Commercial): Once FDA approved, the company anticipates generating revenue through the SVF Cell Injection Therapy procedure. The therapy is designed as a point-of-care procedure that fits into a physician's existing workflow. The procedure is anticipated to be CMS reimbursed with a simple billing process. Revenue will come from the device/procedure itself when commercialized.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

GID BIO develops and plans to commercialize an investigational SVF (Stromal Vascular Fraction) Cell Injection Therapy for knee osteoarthritis, delivered through its proprietary SVF-2 closed-loop, four-step point-of-care tissue processing platform. The procedure harvests a small amount of the patient's own adipose tissue, processes and concentrates over 25 million SVF cells in a sterile disposable canister, and delivers the autologous cellular injection imaging-guided into the knee joint in approximately three hours at an outpatient surgery center. The product is currently investigational and pursuing FDA Premarket Approval following completion of its FDA IDE Phase 3 pivotal clinical trial.

Product overview

GID BIO offers a single investigational therapy built on its proprietary SVF-2 tissue processing platform. The SVF Cell Injection Therapy is a closed-loop, 4-step point-of-care system that harvests adipose tissue from the patient, processes it through the SVF-2 device to isolate stromal vascular fraction cells, confirms therapeutic dosing at over 25 million cells, and delivers the injection imaging-guided into the knee joint—all completed in approximately 3 hours in an outpatient setting without requiring a laboratory or overnight hospital stay. The company is pursuing FDA Premarket Approval (PMA) for commercial use.

Differentiator

Problem solved

Functional benefit

Products and services

• SVF Cell Injection Therapy Investigational Stromal Vascular Fraction (SVF) Cell Injection Therapy for knee osteoarthritis using a patient's own adipose-derived cells, processed at point of care and injected imaging-guided into the intra-articular joint space in approximately three hours as a same-day outpatient procedure. Intended for orthopedic surgeons, sports medicine physicians, interventional orthopedists, and outpatient surgery centers treating knee OA patients seeking long-term alternatives to temporary injections or total knee replacement.
• SVF-2 Technology Platform Modular tissue-processing device platform that harvests a small volume of adipose tissue, filters, washes, and enzymatically dissociates it within a sterile disposable canister, and yields a guaranteed therapeutic dose of over 25 million SVF cells (fibroblasts, mesenchymal stromal progenitors, pericytes, and endothelial cells) at point of care, enabling physicians to deliver autologous cellular therapy in outpatient settings without a laboratory.

Quantifiable outcome

• 73% reduction in knee pain at one year vs. sham control
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• InGeneron: InGeneron commercializes autologous adipose-derived regenerative cell therapies (ARC) for orthopedic and wound-care applications, addressing similar indications and value proposition as GID BIO's SVF therapy.
• Regenexx: Regenexx is a physician-network-based provider of autologous orthopedic biologics (BMAC, platelet-based, and same-day SD protocols) operating in the same interventional orthopedics channel as GID BIO.
• Isto Biologics: Isto Biologics develops cellular and orthobiologic products (e.g., InQu, Influx) for spine and orthopedics, making it a direct comparator in autologous and allogeneic orthobiologic cell-therapy deployment.
• Vericel: Vericel is a commercial-stage autologous cell therapy company (MACI for cartilage defects, Epicel for burns) that directly compares to GID BIO's autologous SVF approach, including clinical-trial-driven commercialization in orthopedics.

Broad incumbents

• Arthrex: Arthrex is a leading orthopedic surgical and biologic device company with autologous platelet systems (ACP) and a deep sales infrastructure into the same sports-medicine and orthopedic surgeon channels GID BIO targets.
• Zimmer Biomet: Zimmer Biomet is the largest pure-play orthopedic device maker, offering knee implants (Persona), HA products (Gel-One), and an active orthopedic regenerative medicine pipeline; this is the natural strategic-acquirer profile for GID BIO.
• Stryker: Stryker is a major orthopedic player whose Sports Medicine and Surgical Solutions divisions—including MAKO robotics—compete and partner in the same knee OA surgical referral pathways targeted by GID BIO.
• Smith+Nephew: Smith+Nephew is a global orthopedic and sports-medicine incumbent with HA viscosupplement and regenerative medicine offerings targeting the same orthopedic surgery channel and CMS-reimbursed patient population as GID BIO.
• Bioventus: Bioventus is an established orthobiologics incumbent offering HA viscosupplementation (Durolane), platelet-rich plasma systems, and bone-marrow aspirate solutions directly competing with GID BIO in the knee OA treatment paradigm.

Emerging players

• Mesoblast: Mesoblast develops allogeneic cellular medicines (remestemcel, rexlemestrocel) with Phase 3 data in inflammatory conditions including chronic low back pain—a comparable late-stage cell-therapy competitor across orthopedic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/gid_bio
• LinkedInlinkedin.com/company/the-gid-group-inc.
• Facebookfacebook.com/GIDBio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GID BIO, Inc.